We respond to new imaging method which could help breast cancer patients avoid extensive surgery

  New ultrasound imaging method found to be as accurate as MRI in assessing the effectiveness of pre-surgery chemotherapy for breast...

4 December 2019

We respond to study suggesting that ‘permanent hair dye and chemical straighteners may increase breast cancer risk’

A new study by the National Institute of Health (US) suggests that using permanent hair dye and chemical straighteners could increase a woman’s...

4 December 2019

We respond to new estimations there are nearly three million people living with cancer in UK

Responding to new research released by Macmillan Cancer Support revealing there are nearly three million people living with cancer in the UK,...

29 November 2019

We respond to NICE approval of palbociclib with fulvestrant for use on the Cancer Drugs Fund

The National Institute for Health and Care Excellence (NICE) has today (28 November 2019) approved palbociclib in combination with hormone therapy...

28 November 2019

We respond to research investigating the possibility of using family history of breast cancer to adapt screening age

New research published in JAMA Oncology demonstrates how it may be possible to use family history of breast cancer to help adapt the starting age for...

21 November 2019

We respond to SMC approval of ribociclib with fulvestrant for use on NHS in Scotland

The Scottish Medicines Consortium (SMC) has today (11 November 2019) announced its decision to approve ribociclib in combination with hormone therapy...

11 November 2019

We respond to ‘simple blood test for early detection of breast cancer’

A new blood test that could detect the early stages of breast cancer is being developed by scientists at the University of Nottingham. The...

4 November 2019

We respond to major new report on NHS cancer screening

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, the research and care charity, said: "It’s extremely promising that these...

16 October 2019

Our response to draft NICE rejection of atezolizumab with nab-paclitaxel

The National Institute for Health and Care Excellence (NICE) has today (3 October 2019) announced its decision to provisionally reject immunotherapy...

3 October 2019